HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)

Posted by ABMN Staff on May 10th, 2024

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 118.07% from the company’s previous close.

Armata Pharmaceuticals Trading Up 16.3 %

Shares of ARMP stock opened at $3.21 on Wednesday. Armata Pharmaceuticals has a twelve month low of $1.07 and a twelve month high of $5.26. The company has a market capitalization of $116.04 million, a price-to-earnings ratio of -1.62 and a beta of 0.96.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.68 million. On average, equities analysts expect that Armata Pharmaceuticals will post -1.34 EPS for the current year.

Institutional Trading of Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) by 80.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,777 shares of the company’s stock after buying an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent SEC filing. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

(Get Free Report)

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.